MONMOUTH JUNCTION, N.J., Sept. 13, 2018 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO) a critical care immunotherapy leader using its CytoSorb® blood purification technology to help patients survive sepsis and other life-threatening inflammatory conditions, commemorates World Sepsis Day 2018 today as a sponsor of the Sepsis Heroes Gala and the Roger Bone Award for Excellence in Sepsis Research.
What is sepsis? Watch this short video!
CytoSorbents will once again proudly sponsor the 7th Annual Celebration of Sepsis Heroes event hosted by the Sepsis Alliance tonight, September 13, 2018, in New York City at Marquee New York (289 10th Avenue) starting at 5:30PM EDT. The sold-out event recognizes individuals and organizations that are making a difference in sepsis awareness. This year’s honorees include Mr. Jay Towers, the University of Michigan Post ICU Longitudinal Survivor Experience (UM-PULSE), Rooks County Health Center, Ms. Jill Kogan Blake, and Ms. Sharon Hansen.
Highlighting the evening will be the Erin Kay Flatley Spirit Award Winner, Ms. Angelica Hale, who before singing her way to the finals of America’s Got Talent, was herself a survivor of sepsis when she was just 4 years old. She will perform two inspirational songs at the gala event, and will be accompanied on the piano by Broadway star, Matt Friedman. Mr. Friedman will be awarded the first ever Scott Alling Entertainer Award, in memory of Mr. Scott J. Alling, a former Board Director of the Sepsis Alliance and a good friend and long-time supporter of CytoSorbents, whose generosity made the last six Sepsis Heroes Galas possible at his Arena event space.
In addition, CytoSorbents will again sponsor the Roger Bone Award for Excellence in Sepsis Research, to be awarded by the German Sepsis Society at this year’s DIVI Critical Care Congress in Leipzig, Germany, to recognize an outstanding publication in clinical sepsis research for young scientists in German-speaking countries. Dr. Bone was a pioneer in understanding the connection between uncontrolled inflammation and organ failure in sepsis pathology and one of the fathers of critical care immunotherapy.
Dr. Phillip Chan, MD, PhD, Chief Executive Officer of CytoSorbents stated, “Sepsis is the overzealous immune response to an infection, and remains one of the top ten causes of death worldwide, despite the use of antibiotics and standard medical care. Only through a coordinated effort of infection prevention, faster recognition, early antibiotic treatment, and aggressive control of deadly inflammation, can we turn the tide on this lethal scourge. We are thankful that our CytoSorb therapy is being increasingly embraced around the world as a powerful new weapon against sepsis.”
Sepsis is a medical emergency that results from of an overzealous immune response to a serious infection, driven by a “cytokine storm”, leading to widespread deadly inflammation that can cause multiple organ failure, immune paralysis, and death. According to the Global Sepsis Alliance, sepsis afflicts approximately 27 to 30 million people each year worldwide, and kills someone every few seconds, despite the use of antibiotics.
CytoSorb® blood purification works to control the excessive inflammatory response through cytokine reduction, removal of bacterial toxins, and redirection of activated white blood cells to the area of infection and away from healthy organs. In doing so, the goal of CytoSorb is to prevent or treat organ failure, the leading cause of death in sepsis. CytoSorb is approved in the European Union, distributed in 53 countries around the world, and has been used in more than 46,000 cumulative treatments. CytoSorb is not yet approved in the U.S.
About World Sepsis Day
World Sepsis Day is an initiative of the Global Sepsis Alliance (GSA) and its founding non-profit members: The World Federation of Societies of Intensive and Critical Care Medicine, the World Federation of Pediatric Intensive and Critical Care Societies, the World Federation of Critical Care Nurses, the International Sepsis Forum, and the Sepsis Alliance. The goals of World Sepsis Day are to:
- Reduce the incidence of sepsis through effective prevention strategies
- Increase sepsis survival rates for all population groups around the world
- Provide better access to suitable rehabilitation services for people everywhere
- Increase awareness and understanding of sepsis among healthcare professionals and the general public
For more information, visit www.world-sepsis-day.org
About the German Sepsis Society
The German Sepsis Society (GSS) is the primary medical society in Germany whose mission is to educate and increase public and professional awareness about sepsis. The organization brings together leaders in sepsis research, diagnostics, treatment, and education in order to also encourage new research, recognize valuable scientific contributions, and foster collaborations to help save lives. A major goal is to support the rapid implementation of effective sepsis diagnostics and therapies into the standard of care treatment for sepsis. Members of the GSS have been heavily involved with SepNet, or the Sepsis Competence Network, a consortium of hospitals and investigators funded for 10 years by the German Federal Ministry of Education to conduct research and clinical trials in sepsis. The GSS also initiated the foundation of the organization, German Sepsis Aid, by people who survived sepsis and their relatives, to provide assistance, information, and networking for those whose lives have been touched by sepsis. For more information, visit www.sepsis-gesellschaft.de/DSG/Englisch
About the Sepsis Alliance™ and Sepsis Heroes Gala
The Sepsis Alliance is a charitable organization run by a team of dedicated laypeople and professionals who share a strong commitment to battling sepsis. The goal is to raise awareness of sepsis through information and educational material so it can be detected and treated early enough that no harm is done. The Sepsis Heroes Gala is an award reception, being held in New York City, designed to raise awareness of sepsis and to recognize the unique contributions of individuals who have committed their time and energy for the cause. For more information, visit www.sepsis.org
About CytoSorbents Corporation (NASDAQ: CTSO)
CytoSorbents Corporation is a leader in critical care immunotherapy, specializing in blood purification. Its flagship product, CytoSorb® is approved in the European Union with distribution in 53 countries around the world, as an extracorporeal cytokine adsorber designed to reduce the “cytokine storm” or “cytokine release syndrome” that could otherwise cause massive inflammation, organ failure and death in common critical illnesses.These are conditions where the risk of death is extremely high, yet no effective treatments exist. CytoSorb® is also being used during and after cardiac surgery to remove inflammatory mediators that can lead to post-operative complications, including multiple organ failure. CytoSorbents recently initiated its pivotal REFRESH 2-AKI trial – a multi-center, randomized controlled, clinical trial intended to support U.S. regulatory approval of CytoSorb for use in a heart-lung machine during complex cardiac surgery to reduce organ injury. CytoSorb® has been used in more than 46,000 human treatments to date.
CytoSorbents’ purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its technologies have received non-dilutive grant, contract, and other funding of approximately $25 million from DARPA, the U.S. Army, the U.S. Department of Health and Human Services, the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), U.S. Special Operations Command (USSOCOM), and others. The Company has numerous products under development based upon this unique patented blood purification technology including CytoSorb-XL™, HemoDefend™, VetResQ™, K+ontrol™, ContrastSorb, DrugSorb, and others. For more information, please visit the Company’s websites at www.cytosorbents.com and www.cytosorb.com or follow us on Facebook and Twitter.
This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as “may,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue” and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management’s current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, the risks discussed in our Annual Report on Form 10-K, filed with the SEC on March 8, 2018, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws.
Please Click to Follow Us on Facebook and Twitter
Investor Relations Contact:
Public Relations Contact:
Rubenstein Public Relations
SOURCE CytoSorbents Corporation